Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Terminated 2Completed 2Unknown 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 32Lymphoid 31Other hematologic neoplasm 26Myeloid 11Genitourinary 11Thoracic 10Gastrointestinal 10Dermatologic 10Breast 10CNS 9Other solid neoplasm 8Sarcoma 5Head & Neck 4Tumor-Agnostic 2Endocrine 2NET 1Classical hematology 1

Conditions

Sarcoma 2Oligodendroglioma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Kidney Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Dendritic Cell Sarcoma, Interdigitating 1Chordoma 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

Radiotherapy 220Doxorubicin 210Cyclophosphamide 210Temozolomide 182Ifosfamide 121Filgrastim 111Imatinib Mesylate 104Etoposide 101Vincristine 92Gemcitabine 89Bevacizumab 83Magnetic Resonance Spectroscopy 80Irinotecan 79pembrolizumab 75Radiation 69Carboplatin 65Methotrexate 62pazopanib 61Nivolumab 58Cisplatin 58fludarabine phosphate 57Peripheral Blood Stem Cell Transplantation 57Surgical Procedures, Operative 56Specimen Handling 56Trabectedin 52Docetaxel 50Biopsy 50Busulfan 49Melphalan 46Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Panobinostat × Sarcoma × Clear all
NCT01282476 2017-05-09

Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Massachusetts General Hospital

Phase 2 Terminated
18 enrolled 20 charts
LymphoidSarcoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT01005797 2017-03-03

Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers

Medical University of South Carolina

Phase 1 Completed
38 enrolled
GenitourinarySarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Sarcoma

NCT01136499 2013-03-06

ESTIM-LBH

Centre Leon Berard

Phase 2 Completed
53 enrolled
Sarcoma

Sarcoma

NCT01175109 2012-12-27

Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma

University of Virginia

Phase 1 Unknown
36 enrolled
Sarcoma

Chordoma

NCT00848523 2010-07-16

Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors

Neurological Surgery, P.C.

Phase 2 Terminated
6 enrolled
CNSSarcoma

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡